RxDoctor Payments Data

April Morrison, MD

Infectious Disease · Warsaw, INNPI 1194759456

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,549 of the $1,738 with a category attached, or 89.1%. 14 manufacturers reported payments, led by Gilead at 35.7% of the total.

$1,738in general payments, 2019–2025

Across 74 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$621
  • Viiv Healthcare Company$398
  • AbbVie$198
  • Janssen Products, LP$130
  • Merck$113
  • Johnson & Johnson$65
  • plus $211 from 8 others

What the payments were for

  • Food & beverage$1,54989%
  • Education$18911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,738 in reported general payments places this provider in the 75th percentile of 152 infectious disease providers in Indiana.

See all infectious disease providers in Indiana

Medicare billing

Part B allowed, 2024
$53,305
Medicare patients
171
Services billed
940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala164$682,875
TriumeqAbacavir/Dolutegravir/Lamivudi67$278,479
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf44$226,904
TivicayDolutegravir Sodium55$156,052
OdefseyEmtricitab/Rilpiviri/Tenof Ala29$103,463
CabenuvaCabotegravir/Rilpivirine14$97,342
DovatoDolutegravir Sodium/Lamivudine29$86,028
PrezcobixDarunavir/Cobicistat22$54,025
DescovyEmtricitabine/Tenofov Alafenam21$48,502
JulucaDolutegravir/Rilpivirine14$46,842
IsentressRaltegravir Potassium12$27,191
Etravirine11$11,689
CeftriaxoneCeftriaxone Sodium39$10,074
ErtapenemErtapenem Sodium16$9,773
Voriconazole29$9,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$621$731,377185 claims
Viiv Healthcare CompanyTriumeq, Tivicay, Cabenuva, Dovato, Juluca$398$664,743179 claims
Janssen Products, LPSymtuza$130$226,90444 claims
Johnson & JohnsonPrezcobix$65$54,02522 claims
MerckIsentress$113$27,19112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 infectious disease providers in Indiana.

Other infectious disease in Warsaw

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →